Proxy Results Form 8 K

On October 17, 2024, Galera Therapeutics, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting"). A total of 32,061,280 shares of common stock were present online or represented by proxy at the Special Meeting, representing approximately 58.94% percent of the Company's outstanding common stock as of the August 27, 2024 record date. The following are the voting results for the proposals considered and voted upon at the Special Meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 3, 2024.

Proposal 1 - The approval of the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the "Plan of Dissolution"), which, if approved, would authorize the board of directors of the Company (the "Board") to liquidate and dissolve the Company in accordance with the Plan of Dissolution (the "Dissolution Proposal").

Proposal 2 - To adjourn the Special Meeting, from time to time, to a later date or dates, even if a quorum is present, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve the Dissolution Proposal.

Based on the foregoing votes, Proposal 1 and Proposal 2 were not approved by the Company's stockholders. The Board will continue to explore what, if any, alternatives are available for the future of the Company in light of its discontinued business activities and lack of resources.